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The risk factors for coronavirus disease 2019 (COVID-19) severity are still poorly
understood. Considering the pivotal role of the gut microbiota on host immune
and inflammatory functions, we investigated the association between changes in the
gut microbiota composition and the clinical severity of COVID-19. We conducted
a multicenter cross-sectional study prospectively enrolling 115 COVID-19 patients
categorized according to: (1) the WHO Clinical Progression Scale—mild, 19 (16.5%);
moderate, 37 (32.2%); or severe, 59 (51.3%), and (2) the location of recovery from
COVID-19—ambulatory, 14 (household isolation, 12.2%); hospitalized in ward, 40
(34.8%); or hospitalized in the intensive care unit, 61 (53.0%). Gut microbiota analysis
was performed through 16S rRNA gene sequencing, and the data obtained were
further related to the clinical parameters of COVID-19 patients. The risk factors for
COVID-19 severity were identified by univariate and multivariable logistic regression
models. In comparison to mild COVID-19 patients, the gut microbiota of moderate and
severe patients have: (a) lower Firmicutes/Bacteroidetes ratio; (b) higher abundance of
Proteobacteria; and (c) lower abundance of beneficial butyrate-producing bacteria such
as the genera Roseburia and Lachnospira. Multivariable regression analysis showed that
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the Shannon diversity index [odds ratio (OR) = 2.85, 95% CI = 1.09–7.41, p = 0.032)
and C-reactive protein (OR = 3.45, 95% CI = 1.33–8.91, p = 0.011) are risk factors
for severe COVID-19 (a score of 6 or higher in the WHO Clinical Progression Scale).
In conclusion, our results demonstrated that hospitalized patients with moderate and
severe COVID-19 have microbial signatures of gut dysbiosis; for the first time, the gut
microbiota diversity is pointed out as a prognostic biomarker of COVID-19 severity.
Keywords: COVID-19, WHO Clinical Progression Scale, Shannon—Weiner diversity index, dysbiosis, gut
microbiota
INTRODUCTION
Coronavirus disease 2019 (COVID-19), caused by the novel
severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) infection, is clinically diverse in terms of disease
severity—ranging from absence of symptoms to mild, self-
limiting respiratory illness (including the common cold), severe
pneumonia, acute respiratory distress syndrome, and death
(Chen et al., 2020). COVID-19-induced respiratory distress
syndrome was described to be associated with exuberant
inflammation, intense cytokine production (cytokine storm
syndrome), and multi-organ dysfunction (Chen et al., 2020;
Marini and Gattinoni, 2020). Although respiratory symptoms
are the most commonly reported among COVID-19 patients,
gastrointestinal symptoms are also likely between SARS-CoV-2-
infected patients, indicating that the gastrointestinal tract is an
infected organ as well (Mao et al., 2020). In consequence, SARS-
CoV-2 is detected in the feces of some COVID-19 patients (Wu
et al., 2020b; Guo et al., 2021; Zuo et al., 2021).
Although the risk groups for severe COVID-19 were identified
as being primarily the elderly and individuals with comorbidities,
such as hypertension and diabetes (Petrakis et al., 2020; Wang
D, et al., 2020; Zhou et al., 2020), COVID-19 may evolve
adversely even in individuals without comorbidities, causing
severe pneumonia, long-term sequelae, and, eventually, death
(WHO, 2020). These observations suggest the existence of
major predisposition factor(s) related to disease progression that
need(s) to be urgently unveiled.
The human gut microbiota, mainly composed of bacteria,
plays a critical role in health and most notably in host
immune response, including vaccine efficacy (Ciabattini et al.,
2019; Vlasova et al., 2019). Changes in the gut microbiota
composition have been reported to affect both vulnerability
and disease outcomes in non-communicable diseases, such as
diabetes, inflammatory bowel disease, and obesity, leading to
a state of chronic low-grade inflammation (Leocadio et al.,
2019; Noce et al., 2019; Finlay et al., 2020). This role of the
gut microbiota in both immune and inflammatory responses,
together with the fact that SARS-CoV-2 binds to angiotensin-
converting enzyme (ACE) 2 receptors on the gut epithelium
(Ye et al., 2020), where it has been detected along the feces of
COVID-19 patients (Xiao et al., 2020), suggests the existence
of a microbial fingerprinting among these patients that may
provide a predictive value for disease severity. Accordingly,
gut microbiome characterization has been assessed in COVID-
19 patients, which unveiled profound alterations on bacterial
composition (Zuo et al., 2020, 2021; Yeoh et al., 2021). The
depletion of beneficial bacteria from the taxa Lachnospiraceae
and the genera Bifidobacterium, Faecalibacterium, and Roseburia
(Gu et al., 2020; Zuo et al., 2020; Yeoh et al., 2021) has been
proposed as having an impact on the modulation of host immune
response to SARS-CoV-2 infection and potentially influenced
disease severity and outcomes (Yeoh et al., 2021). However,
existing studies did not enroll COVID-19 patients representative
of the different COVID-19 severity levels, lacking mainly
patients with severe clinical manifestations. Most importantly,
previous studies did not clarify whether the observed changes
in microbiota composition are a common patient’s response
to SARS-CoV-2 infection rather than directly involved in
disease severity.
Taking this into consideration, we investigated the association
between the gut microbiota and COVID-19 disease severity
using a cohort of 115 patients stratified as asymptomatic/mild–
moderate–severe according to the WHO Clinical Progression
Scale. Considering that previous studies have shown no
significant alterations in the gut microbiota during COVID-
19 disease progression and even after SARS-CoV-2 clearance
(Zuo et al., 2020; Yeoh et al., 2021), a single fecal sample was
collected. The clinical variables and gut bacterial composition
were compared between the COVID-19 severity groups. The role
of antibiotic use was also addressed. To the best of our knowledge,
this is the largest study assessing the gut microbiota composition
in patients with COVID-19 and the first outside of China.
RESULTS
Clinical Characteristics of COVID-19
Patients
A total of 115 adults (median age = 68 years, 63.5% males)
with a laboratory-confirmed positive test for SARS-CoV-2 were
included in our study (Table 1). More than half (65.7%) were
overweight or obese, and regarding comorbidities, 45 patients
(42.1%) had diabetes, 67 (62.0%) had hypertension, and 21
(19.6%) had chronic respiratory disease (Table 1). Concerning
antibiotic exposure, 42 patients (38.9%) were administered with
antibiotics at least once during the 6 months prior to COVID-
19 diagnosis (Table 1) and 108 (85.2%) were administered
antibiotics during the course of COVID-19. Previous chronic
therapy is not associated with COVID-19 severity (p = 0.403;
Table 1).
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TABLE 1 | Clinical characteristics of the COVID-19 patients.







(N = 115) (N = 19) (N = 37) (N = 59)
Age, median (IQR) (years) 68.0 (52.0–76.0) 61.0 (40.0–73.0) 71.0 (52.0–79.0) 66.0 (53.0–76.0) 0.305a
Male sex, n (%) 73 (63.5) 6 (31.6) 24 (64.9) 43 (72.9) 0.032b
Overweight or obese, n
(%)
69 (65.7) 7 (70.0) 24 (66.7) 38 (64.4) 0.749b
Smoker, n (%) 21 (19.8) 2 (18.2) 5 (13.9) 14 (23.7) 0.467b
Pneumonia SARS-CoV-2,
n (%)
84 (83.2) 2 (25.0) 24 (70.6) 58 (98.3) <0.001b
C-reactive protein,
median (IQR) (mg/L)
72.0 (28.3–158.9) 32.2 (17.9–54.5) 63.5 (11.5–115.6) 96.8 (34,0–177.0) 0.063a
Coexisting conditions, n
(%)
Diabetes 45 (42.1) 2 (16.7) 14 (38.9) 29 (49.2) 0.099b
Hypertension 67 (62.0) 4 (33.3) 27 (73.0) 36 (61.0) 0.811b
Chronic respiratory
disease
21 (19.6) 2 (16.7) 5 (13.9) 14 (23.7) 0.236b




9 (8.5) 2 (16.7) 3 (8.6) 4 (6.8) 0.479b
Medication history, n (%)
Previous chronic therapy 86 (86.9) 8 (100.0) 29 (87.9) 49 (84.5) 0.403b
Antibiotic therapy (last
6 months)
42 (38.9) 5 (41.7) 17 (45.9) 20 (33.9) 0.243b
Patients were classified in accordance with the WHO Clinical Progression Scale. This scale provides a measure of illness severity across a range from 0 (not infected with
SARS-CoV-2) to 10 (dead). Patients were grouped into three categories: mild disease (scores 1–3), moderate disease (scores 4–5), and severe disease (scores 6–9). IQR,
interquartile range aKruskal–Wallis test. bChi-square test. Bold values indicate statistical significance with a *p < 0.05.
According to the location of recovery, the proportion of
patients with diabetes attending the intensive care unit (ICU)
was significantly higher than the proportion of patients with
diabetes isolated in a ward or those ambulatory (31 vs. 14 patients,
p < 0.05). Similarly, the proportion of patients presenting three
simultaneous comorbidities (obesity, hypertension, and diabetes)
was higher in ICU patients than in those isolated in the ward or
ambulatory (22 vs. 5 patients, p < 0.05).
Fecal Microbiota Profile According to
COVID-19 Severity
From the initial 115 COVID-19 patients, we were able to obtain
a sufficient amount of good quality fecal DNA to perform
microbial composition based on 16S ribosomal RNA (rRNA)
gene analysis in 111 patients (96.5%). The gut microbiome
of the COVID-19 patients was compared based on the fold
change of relative abundance (medians) for each bacterial genus.
For this comparison, the COVID-19 patients were grouped
according to the disease severity defined by the WHO Clinical
Progression Scale (WHO Working Group on the Clinical
Characterisation and Management of Covid-19 infection, 2020).
This scale provides a measure of illness severity, in which a
higher score means a higher disease severity. Eighteen COVID-
19 patients were classified as asymptomatic/mild (scores 1–3),
36 were categorized as moderate (4–5), while 57 were severe
(scores 6–9). Three comparisons were done: (1) severe vs.
asymptomatic/mild; (2) severe vs. moderate; and (3) moderate
vs. asymptomatic/mild (hereinafter referred to as mild). In order
to determine the relative taxonomic changes at the genus level
between the COVID-19 severity groups, a heat tree was built
for each comparison (Figure 1A), in which the terminal nodes
correspond to the bacterial genera. For the first time, our data
show that differences in the gut microbiome occur across all
phyla, with the exception of Synergistetes and Verrucomicrobia,
and the relative abundance is in general higher in less severe
COVID-19 states. The higher number of alterations was observed
between mild and moderate COVID-19 patients and between
the mild and severe states. Fewer alterations were detected
between the moderate and severe states of COVID-19. Globally,
the relative abundances tend to be higher in mild than in
moderate patients; in turn, the relative abundances tend to be
higher in moderate than in severe COVID-19 patients. This
decrease tendency from mild to moderate to severe is observed in
the bacterial families Bifidobacteriaceae (Bifidobacterium genus)
and Coriobacteriaceae (genus Collinsella), being statistically
significant in the family Lachnospiraceae, namely, in the genera
Roseburia and Lachnospira [p < 0.001, false discovery rate
(FDR)-corrected]. In the opposite direction, the genus Ralstonia
(Proteobacteria) increases with the COVID-19 severity score
(p < 0.001, FDR-corrected).
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FIGURE 1 | Comparison of coronavirus disease 2019 (COVID-19) gut microbiome with COVID-19 severity. Disease severity was determined according to the WHO
Clinical Progression Scale: mild, moderate, and severe. (A) Heat tree visualization of the taxonomic differences between the COVID-19 severity groups based on the
Log2 ratio median abundance (proportions), in which the terminal nodes correspond to bacterial genera. The identification of the nodes is shown in the bottom left
image. Three comparisons were done: severe (blue green) vs. mild (orange); severe (blue green) vs. moderate (orange); and, ultimately, moderate (blue green) vs.
mild (orange). The dominant color corresponds to a higher number of operational taxonomic units (OTUs). The Log2 ratio is 0 (gray) when the compared groups are
similar. (B) The Shannon diversity index (mean + SEM) of the COVID-19 patients according to the WHO Clinical Progression Scale, from score 1 (asymptomatic, viral
RNA detected) to score 9 (mechanical ventilation pO2/FiO2 < 150 and vasopressors, dialysis, or ECMO).
In accordance with the inverse relation between the relative
abundance of bacterial gut microbiota and COVID-19 severity
score, Shannon’s diversity index showed a similar tendency, being
higher in mild than in moderate and severe COVID-19 patients,
with a mean values of 2.28 ± 0.30 (scores 1–3), 2.16 ± 0.40 (scores
4–5), and 2.10 ± 0.42 (scores 6–9), respectively (Figure 1B).
Fecal Microbiota Profile According to
COVID-19 Location of Recovery
As an indirect measure of the COVID-19 severity grade, the
COVID-19 patients were grouped according with the location
of recovery. Location of recovery and the WHO Clinical
Progression Scale are related classifications; however, only the
WHO scale provides a real measure of illness severity. Of the
111 COVID-19 patients with characterized fecal microbiota, 59
(53.2%) required ICU admission, 39 (35.1%) were hospitalized
in a ward, and 13 (11.7%) were ambulatory (household
isolation). Patient distribution by COVID-19 location of recovery
(ambulatory–ward–ICU) does not totally overlap with the
distribution by the WHO Clinical Progression Scale (mild–
moderate–severe). There were some patients hospitalized in
the ICU with moderate disease severity; also, there were other
patients isolated at home with moderate symptoms.
The gut microbiome composition of all COVID-19 patients
distributed by COVID-19 location of recovery was compared
using the non-metric multidimensional scaling tool (Figure 2A).
The fecal microbiota communities of COVID-19 patients
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FIGURE 2 | Fecal microbiota composition of coronavirus disease 2019 (COVID-19) patients according to patient location of recovery: ambulatory, hospitalized in
ward, or hospitalized in ICU. (A) Fecal microbiota community alterations according to patient location in the NMDS2 (non-metric multidimensional scaling) plot based
on the Bray–Curtis dissimilarity. (B) Main bacterial phyla in the fecal samples of COVID-19 patients according to patient location. (C) Box plot of the alpha diversity
(measured by the Shannon diversity index) of the COVID-19 patients according to patient location.
recovering in ambulatory were more similar compared to
the microbiota from those recovering in the ward and in
the ICU [p < 0.05, permutational multivariate ANOVA
(PERMANOVA)]. The comparison of the relative abundance at
the phylum level between the three groups unveiled a consistent
trend of an increase in the relative abundance of Proteobacteria
from 3% in ambulatory patients to 12 and 14% in ward and ICU
patients, respectively (Figure 2B). The Firmicutes/Bacteroidetes
ratio decreased in COVID-19 patients from ambulatory–ward–
ICU (0.68, 0.65, and 0.58, respectively). As observed for the
WHO severity groups, the COVID-19 patients hospitalized in the
ICU tended to have lower alpha diversity (Shannon’s index) in
comparison to ambulatory and in ward/hospitalized COVID-19
patients (Figure 2C), as suggested by the lower mean and the first
and third quartile values.
Clinical Characteristics Associated With
COVID-19 Severity
Univariate and multivariate logistic regression models were
used to evaluate the associations between patients’ clinical
characteristics and COVID-19 severity (Table 2). Our aim was
to develop a prognostic model able in order to predict the
occurrence of certain outcomes in severely vs. mild to moderately
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ill patients. The univariate model showed that severe COVID-
19 patients were more likely to be men and to have elevated
blood levels of C-reactive protein (CRP) compared with mild
to moderate COVID-19 patients. The association between male
gender and higher severity of COVID-19 can be explained by
the higher proportion of men (72.9%) with severe COVID-19
in comparison to women. The age, body mass index, Shannon’s
diversity index, comorbidities (hypertension and diabetes), and
antibiotic therapy (at least once in the 6 months before COVID-
19) were not significantly different between mild to moderate and
severe patients. Regarding antibiotic therapy during the course
of COVID-19, this variable was not significantly associated with
COVID-19 severity (OR = 2.05, 95% CI = 0.55–7.73, p = 0.287).
In the multivariate model mutually adjusted for CRP,
Shannon’s diversity index, age, and antibiotic therapy 6 months
prior to COVID-19 diagnosis, the variable CRP and Shannon’s
diversity index were significantly associated with COVID-19
severity, while gender was no longer significantly associated
(Table 2). Accordingly, the probability of having severe disease
is 3.45 times higher when the CRP level is ≥ 96.8 mg/L. Likewise,
the probability of having severe COVID-19 symptoms is 2.85
times higher when the Shannon diversity index is lower than
2.25. The geographic areas of the participating centers did not
have an impact on our multivariate regression model, showing
that disease severity and Shannon’s diversity index outcomes
are center-independent. No correlation was found between the
Shannon diversity index and clinical variables related to COVID-
19 severity, such as duration of mechanical ventilation, ICU
length of stay, ICU mortality, and 28-day mortality.
The discriminative/predictive power of the model was
evaluated by receiver operating characteristic (ROC) curve
analysis. The ROC analysis revealed an acceptable discriminative
power of the model, with an area under the curve (AUC) of 0.707
(95% CI = 0.600–0.814) (Supplementary Figure 1). Furthermore,
our model correctly predicted 56.4 and 78.9% of patients with
mild to moderate and with severe disease, respectively.
Fecal Microbiota Profile in Patients
Positive for SARS-CoV-2 in Feces
With regard to some authors suggesting that fecal microbiota
alterations are associated with the presence of SARS-CoV-2 in the
gastrointestinal tract (Wolfel et al., 2020; Zuo et al., 2020; Yeoh
et al., 2021), we analyzed the presence of SARS-CoV-2 RNA in
feces. There was sufficient amount of good quality fecal RNA to
detect SARS-CoV-2 RNA in 112 (97.4%) among the 115 recruited
patients. From the 112 samples analyzed, 45 tested positive (40%
of the COVID-19 patients). Interestingly, the virus was detected
mostly in men than in women (61.3 and 38.7%, respectively,
p < 0.05). We then investigated whether the presence of the
virus in feces was associated with changes in the gut microbiota
composition. As depicted in Figure 3A, no major differences
were found in the distribution of the most abundant phyla and
genera between patients positive and negative for SARS-CoV-
2 in feces. Subsequently, we assessed the association between
fecal SARS-CoV-2 positivity and the COVID-19 severity score or
location of recovery using Pearson’s chi-square test. Importantly,
no association was verified between the two categorical variables
(p-values of 0.31 and 0.57 for the severity score and location of
recovery, respectively). Nevertheless, we found a strong tendency
for a lower Shannon’s diversity index in the feces of SARS-CoV-2
positive patients (p = 0.06; Figure 3B).
DISCUSSION
We conducted a multicenter prospective cross-sectional study
with 115 COVID-19 patients in different COVID-19 severity
stages under the hypothesis that gut microbiota dysbiosis plays
a pivotal role in the pathophysiology of COVID-19, namely, in
the severity of its clinical course.
In order to determine the association between the gut
microbiota composition and COVID-19 disease severity, the
clinical and 16S rRNA gene sequencing data from COVID-19
patients were analyzed and subsequently clustered according
to: (i) the severity of COVID-19 using the WHO Clinical
Progression Scale, i.e., mild, moderate, or severe, and (ii)
the location of recovery from COVID-19, i.e., ambulatory,
hospitalized in ward, or hospitalized in ICU. Our data showed
for the first time an inverse association between relative bacterial
abundance at the genus level and Shannon’s index diversity
with COVID-19 disease severity (Figure 4). According to our
multivariable model, CRP ≥ 96.8 mg/L and a Shannon diversity
index < 2.25 were associated with higher severity (a score
of 6 or more in the COVID-19 WHO Clinical Progression
Scale), suggesting that these patients’ variables are predictors of
severe COVID-19. The data showed no correlation between the
gut microbiota diversity (Shannon’s index) and the CRP levels.
However, we cannot rule out a possible relation between the two
biomarkers, and the possibility of crosstalk should be investigated
in a larger study.
Our multivariable model correctly predicted 79% of patients
with severe COVID-19. A cross-sectorial study including
a larger population size is necessary to produce a more
powerful multivariable logistic regression model that will
predict a higher percentage of patients with severe COVID-
19. Furthermore, other clinical variables that were not reported
in this study could also contribute to improve the predictive
and discriminative power of the model. Indeed, a recent
study has demonstrated correlations between intestinal bacteria
and interleukins, chemokines, and tumor necrosis factor-
alpha, proposing that the gut microbiota could modulate the
inflammatory immune response (Yeoh et al., 2021).
Interestingly, fecal SARS-CoV-2 was detected in COVID-19
patients who tend to have lower Shannon’s diversity (p = 0.06).
We did not detect an association between fecal SARS-CoV-2
positivity and COVID-19 severity score (p = 0.31). However,
this result should not be over-interpreted since a one-point fecal
sample was collected, and thereby it cannot be excluded that
patients with negative fecal SARS-CoV-2 could become positive
during COVID-19 disease progression.
In comparison to mild COVID-19 patients, the gut microbiota
from moderate and severe COVID-19 patients tended to
have: (1) decreased Firmicutes/Bacteroidetes ratio (0.68 in mild
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TABLE 2 | Bivariate logistic regression analysis of the clinical variables associated with severity of COVID-19 (a score of 6 or more in the WHO Clinical Progression Scale).
Variable Crudea ORb (95% CI) p-value Adjusteda ORb (95% CI) p-value
Gender Female (n = 42) 1.0 0.033
Male (n = 73) 2.33 (1.07–5.07)
Age <65 year (n = 48) 1.0 0.603
≥65 (n = 67) 0.82 (0.39–1.73)
C-reactive protein <96.8 mg/L (n = 58) 1.0 0.022 1.0 0.011
≥96.8 mg/L (n = 41) 2.73 (1.15–6.46) 3.45 (1.33–8.91)
Shannon diversity index ≥2.25 (n = 46) 1.0 0.164 1.0 0.032
<2.25 (n = 65) 1.72 (0.80–3.68) 2.85 (1.09–7.41)
Overweight or obese BMI < 25 (n = 36) 1.0 0.749
BMI ≥ 25 (n = 69) 0.88 (0.39–1.98)
Hypertension Normal (n = 41) 1.0 0.811
Hypertension (n = 67) 0.91 (0.42–1.99)
Diabetes Normal (n = 62) 1.0 0.101
Diabetes (n = 45) 1.93 (0.88–4.25)
Antibiotic therapy (last 6 months) Without (n = 66) 1.0 0.244
With (n = 42) 0.63 (0.29–1.37)
95% CI, 95% confidence interval; OR odds ratio; BMI, body mass index. aCrude ORs were calculated using univariate weighted logistic regression models. Adjusted ORs
were calculated using multivariate weighted logistic regression models. Fully adjusted estimates take into account four variables (age, antibiotic therapy at least once in
the last 6 months, C-reactive protein, and the Shannon diversity index) in the model (n = 96). bRisk (OR) of severity of COVID-19 (a score of 6 or more in the WHO Clinical
Progression Scale). Bold values indicate statistical significance with a *p < 0.05.
compared to 0.65 and 0.58 in moderate and severe COVID-
19, respectively); (2) higher abundance in Proteobacteria (3% in
mild compared to 12 and 14% in moderate and severe COVID-
19, respectively); (3) lower abundance of butyrate-producing
bacteria from the family Lachnospiraceae, in particular the
genera Roseburia and Lachnospira; and (4) lower abundance of
the phylum Actinobacteria, namely, the genera Bifidobacteria
and Collinsella. All these alterations are well-known microbial
signatures of dysbiosis in the gut microbiota (Shin et al., 2015;
Binda et al., 2018; Adelman et al., 2020; Magne et al., 2020).
The Firmicutes/Bacteroidetes ratio has been used to evaluate
gut microbiota dysbiosis; an increase or a decrease in this ratio
is a hallmark of dysbiosis, the former being usually associated
with obesity while the latter with inflammatory bowel disease
(Stojanov et al., 2020). The observed modifications in the
gut microbiota corresponded to a single-point fecal sample
collection; therefore, we cannot exclude that other alterations can
occur during COVID-19 disease progression.
Commensal bacteria play a fundamental role in the
homeostasis of both the immune and inflammatory functions
of the gut (Belkaid and Hand, 2014). Anaerobic bacteria from
the family Lachnospiraceae, such as the genera Roseburia
and Lachnospira, produce butyrate, a short-chain fatty acid
known to exert anti-inflammatory effects in the intestinal
epithelium (Segain et al., 2000). Despite not being butyrate
producers themselves, Bifidobacterium species are able to
cross-feed butyrate-producing bacteria through the secretion
of fermentation end-products such as acetate (Riviere et al.,
2016). This may constitute a potential mechanism by which
Bifidobacterium species (Munoz et al., 2011; Li et al., 2016)
counteract intestinal viral infections. Another mechanism
might be related to their capacity to decrease the production of
pro-inflammatory cytokines (e.g., tumor necrosis factor alpha
and interferon gamma) and increase the production of anti-
inflammatory cytokines (e.g., interleukins 4 and 10) (Sarkar and
Mandal, 2016). Taking all these into consideration, we propose
that changes in the gut microbiota composition observed in
severe COVID-19 patients may eventually act as a trigger to
promote mucosal inflammation and increased gut permeability
to pro-inflammatory molecules. Consequently, this may induce
a state of systemic inflammation since these patients exhibit
higher levels of blood CRP, a recently recognized prognostic
factor for COVID-19 severity (Wang G, et al., 2020). Likewise,
a blood CRP concentration ≥ 96.8 mg/L is associated with a
score of 6 or more in the COVID-19 WHO Clinical Progression
Scale, in accordance with our multivariate model. The increase
of Proteobacteria, a proposed signature of disease (Rizzatti et al.,
2017) particularly of epithelial dysfunction (Litvak et al., 2017), in
severe COVID-19 patients sustains our observation of a relation
between microbiota dysbiosis and the severity of COVID-19
disease. Nevertheless, our observational study did not allow us
to clarify whether the dysbiosis is directly involved in disease
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FIGURE 3 | Fecal microbiota composition of the coronavirus disease 2019 (COVID-19) patients according to the presence of SARS-CoV-2 in fecal samples.
(A) Main bacterial phyla and (B) box plot of the alpha diversity (measured by the Shannon diversity index) of COVID-19 patients according to the presence of
SARS-CoV-2 in fecal samples.
severity or could be a response to disease severity, despite an
association between the gut microbiota and COVID-19 severity
being demonstrated. The nature of this relation should be
further explored.
Interestingly, men COVID-19 patients seemed more prone
to severe disease when compared with women COVID-19
patients (p = 0.032). This gender discrepancy, which has been
described in other clinical trials (Wu et al., 2020a), might
be explained by the higher expression of ACE2 (Song et al.,
2020) in intestinal epithelial cells. This protein receptor is
required for SARS-CoV-2 binding, invasion, and persistence in
host epithelial cells (Trottein and Sokol, 2020). Furthermore,
COVID-19 patients who tested positive for the presence of
SARS-CoV2 in feces were mostly men (p < 0.05), which
reinforces the involvement of intestinal ACE2 in the severity
of the course of the disease. The ACE2 receptor and the gut
microbiota seem to be reciprocally regulated; some gut bacterial
species seem to modulate colonic ACE2 expression (Geva-
Zatorsky et al., 2017), while ACE2 regulates the production of
antibacterial peptides through tryptophan transport, which, in
turn, influences the gut microbiota composition (Hashimoto
et al., 2012; Penninger et al., 2021).
Our findings are consistent with two previous cross-sectional
studies with COVID-19 patients carried out in Hong Kong
(China) (Zuo et al., 2020; Yeoh et al., 2021). The similarity
of our results, collected in Portugal (a southwestern European
country), to those of the geographically far distant Chinese
population led us to conclude that gut microbiota dysbiosis
is a bona fide predictor of COVID-19 severity, and the
microbiome-based risk stratification should be considered in the
management of SARS-CoV-2 infection susceptibility, in parallel
with the worldwide-scale vaccination against COVID-19. Thus,
our study opens perspectives for the development of therapeutic
interventions that aim to correct dysbiosis in severe COVID-19
patients. These include dietary modifications, administration of
butyrate-producing probiotics or prebiotics, and fecal microbiota
transplantation from healthy donors (Friedland and Haribabu,
2020), shown to be effective in recurrent Clostridium difficile
infection (Quraishi et al., 2017). These interventions are expected
to increase the overall bacterial diversity and the abundance
of commensal bacteria, thereby contributing to inhibit the
overgrowth of bacteria from phylum Proteobacteria.
In summary, we revealed for the first time an association
between the gut microbiota and the WHO Clinical Progression
Scale, which reflects patient trajectory during COVID-19.
Our data showed that gut microbiota dysbiosis is present in
moderate and severe COVID-19 patients in comparison to
asymptomatic/mild patients. Importantly, the evidence from
this study suggests that CRP and gut microbiota diversity are
prognostic biomarkers for severe COVID-19.
MATERIALS AND METHODS
Study Design and Population
This national multicenter cross-sectional study was conducted
in six geographically different Portuguese centers selected by
invitation. The distributions of patients per participating center
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FIGURE 4 | Schematic representation of the predictive microbial fingerprint for coronavirus disease 2019 (COVID-19) severity. Preexistent influences on the
microbiota, such as lifestyle and environmental factors, and antibiotics can induce dysbiosis (red arrow), leading to increased inflammation (e.g., CRP levels). Hence,
lower overall microbial diversity and abundance of beneficial commensal microorganisms (e.g., Roseburia), along with an increased abundance of Proteobacteria,
are associated with high COVID-19 severity (a score of ≥ 6 in the WHO Clinical Progression Scale). CRP, C-reactive protein.
were 38 (33.0%), 33 (28.7%), 18 (15.7%), 12 (10.4%), 8
(7.0%), and 6 (5.2%). Patients’ eligibility criteria included age
18 years or above and a positive test for SARS-CoV-2 by
nasopharyngeal swabs using quantitative RT-PCR performed
in national reference laboratories and in accordance with the
recommendations from the National Directorate of Health.
COVID-19 patients were recruited during the first wave of
the pandemic in Portugal—from April 21, 2020, to July 1,
2020—and sample size was determined based on the feasibility
of recruitment during this period. The minimally detectable
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effect sizes were calculated retrospectively. In order to achieve
a statistical power of 80% and a two-sided significance level of
0.05, and considering the total sample size of 115 individuals,
the study was powered to detect a mean difference of 0.15 in the
Shannon diversity index between mild to moderate and severe
COVID-19 patients.
Participating centers prospectively collected data from
consecutive patients included in the study and classified
them according to the location of recovery (ambulatory and
hospitalization in a ward or in the ICU) and the disease
severity using the WHO Clinical Progression Scale (mild,
moderate, and severe) (WHO Working Group on the Clinical
Characterisation and Management of Covid-19 infection, 2020).
The ethics committees and institutional review boards from the
participating centers approved the study protocol, considering
it a minimal-risk research using data collected for routine
clinical practice, and waived the requirement to obtain informed
consent. Patients (or their proxies) received written information
about the study and were informed of their right to refuse to
participate. The study was registered at ClinicalTrials.gov, no.
NCT04355741. All authors had access to the study data and
reviewed and approved the final version of the manuscript.
Data Collection
Patient demographic characteristics, severity scores, smoking
habits, comorbidities prior to hospitalization (diabetes,
hypertension, chronic respiratory diseases, immunosuppression,
hematological oncological disease, previous chronic therapy,
and others), or antibiotic exposure 6 months prior to COVID-
19 diagnosis were recorded for all patients at baseline (i.e.,
immediately after subject enrollment). Data on the clinical
presentation of COVID-19, CRP levels, and the antibiotic,
antiviral, and steroid treatments received during the course of
the disease, as well as nutritional and respiratory support (as per
the WHO Clinical Progression Scale) (WHO Working Group,
2020), were collected. In addition, clinical outcomes such as
the duration of mechanical ventilation, ICU length of stay, ICU
mortality, and 28-day mortality were also collected. Patients were
followed up until hospital discharge, if that was the case.
Stool Collection
Fecal samples of COVID-19 patients were collected after subject
enrollment (single-point collection). The samples were collected
with a stool collection kit (EasySampler, ALPCO, Salem, NH,
United States) containing RNAlater (Sigma-Aldrich, St. Louis,
MO, United States). The fecal samples were kept at −80◦C until
nucleic acid extraction.
Gut Microbiota
Genomic DNA was extracted and purified from the stool samples
of COVID-19 patients using the NZY Tissue gDNA Isolation Kit
(NZYTech, Lisbon, Portugal). All 16S DNA libraries (V3 and V4
regions) were prepared, sequenced, and analyzed in accordance
with the manufacturer’s instructions for each kit and instrument.
Briefly, 16S DNA libraries were prepared using the Ion 16STM
Metagenomics Kit targeted panel (Thermo Fisher Scientific,
Waltham, MA, United States), and each sample was individually
identified with the Ion XpressTM Barcode Adapters Kits (Thermo
Fisher Scientific). All available regions were amplified using the
Ion 16STM Metagenomics Kit (Thermo Fisher Scientific). The
amplified fragments were then prepared for sequencing using the
Ion CHEF System (Thermo Fisher Scientific) and loaded into Ion
318 Chip Kit v2 BC (Thermo Fisher Scientific). Sequencing runs
were performed on an Ion S5 System (Thermo Fisher Scientific),
aiming for a mean sequencing depth coverage of 12,000×. The
sequencing depths were not normalized in order to achieve
better identification of the alpha diversity in each sample. The
sequencing data were filtered for length (cutadapt −m 80) and
for quality (fastx_trimmer −l 280), after which the V3 and V4
regions were extracted (Mothur align.seqs and screen.seqs). The
resulting fastq file was used for taxonomy. The taxonomy of each
sample was determined using Kraken21 and Bracken2 software,
using our custom 16S database (GutHealth_DB). This database
was manually curated by enriching GreenGenes (versions 13_5
and 13_8) with the clinically relevant taxa from NCBI RefSeq 16s
rRNA sequences (04/2019). GutHealth_DB currently holds 4,765
16s rRNA sequences mapping 1,822 species, 1,685 genera, 515
families, 404 orders, 248 classes, and 89 phyla and is available
upon request. Bacterial species were identified as pathogens
or commensals according to The National Microbial Pathogen
Database Resource (NMPDR)3. The datasets presented in this
study can be found in the BioProject database4 with the accession
number PRJNA734646.
Detection of SARS-CoV-2 in Feces
The following steps were taken to detect SARS-CoV-2 in feces: (1)
RNA extraction by the NucliSENS easyMAG technology based
on the Boom technique that utilizes magnetic silica particles
from 200 to 300 mg of stool and (b) detection of SARS-CoV-
2 extracted RNA by the EURORealTime SARS-CoV-2 test. The
latter is based on reverse transcription to convert viral RNA
into complementary DNA, followed by PCR amplification and
fluorescence-based real-time detection of two defined sections
within the ORF1ab and N genes of the SARS-CoV-2 genome.
Reverse transcription, amplification, and detection of SARS-
CoV-2 cDNA were carried out by means of SARS-CoV-2-specific
primers and probes.
Statistical Analysis
Statistical analysis was performed using the SPSS version 27
software (SPSS Inc., Chicago, IL, United States) and R statistical
software package V.3.5.1. Descriptive statistics are presented
as numbers and percentages for categorical variables, as the
mean and standard deviation (SD) for continuous variables, or
as medians with interquartile ranges (IQRs) if the continuous
variable is not normally distributed. Parametric (Student’s t-test
and one-factor ANOVA) and non-parametric (Mann–Whitney
and Kruskal–Wallis tests) tests were used as appropriate, taking
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compared. The Kolmogorov–Smirnov test was used to test
normality assumptions of the variable distributions. Chi-square
test and Fisher’s exact test were used as appropriate, for
categorical variables.
Univariate and multivariate weighted logistic regression
models were used in order to evaluate the risk factors associated
with the severity of COVID-19 (a score of 6 or more in the
WHO Clinical Progression Scale). The dependent variable in all
models was the severity of COVID-19. Independent variables are
indicated in the table legends (Table 2). The Hosmer–Lemeshow
statistic and test was applied to evaluate the goodness of fit. The
discriminative/predictive power of the model was evaluated by
the ROC curve analysis. The influence of outlier data values on
model fit was estimated using leverage statistics, and collinearity
was assessed by evaluation of the coefficients’ correlation matrix.
The results are presented as crude and adjusted ORs and their
respective 95% confidence intervals. The statistical significance
level was set at 5%, and differences were considered statistically
significant when p < 0.05.
Heat tree visualization of the taxonomic differences between
the COVID-19 severity groups was produced using the R package
metacoder. Coloring indicates all differences between the median
proportion of reads for the samples from patients grouped
according to the severity of COVID-19 using the WHO Clinical
Progression Scale, i.e., mild (scores 1–3), moderate (scores 4–
5), and severe (scores 6–9) disease, as determined using a
Wilcox rank-sum test followed by a Benjamini–Hochberg (FDR)
correction for multiple testing.
Alpha diversity was measured by the Shannon diversity index
that summarizes both the species richness (total number of
species) and evenness (abundance distribution across species)
within a sample. The distances (or dissimilarity) between samples
of the same group were compared to the distances between
groups using PERMANOVA.
Missing Data Management
Considering that multiple imputation can give rise to biased
results when missing data are not random (Hughes et al., 2019),
regression analyses were based on complete data. In addition, a
sensitivity analysis was performed using multiple imputations in
order to account for missing data, with five imputed datasets and
10 iterations. All analysis results were aggregated with Rubin’s
rule after appropriate transformation (Graham, 2020).
The sensitivity analysis in which the missing clinical variables
were imputed by means of model-based multiple imputation
showed similar results to the statistical analysis performed with
complete cases (Shannon’s diversity index: OR = 2.71, 95%
CI = 1.13–6.52, p = 0.026; CRP: OR = 4.42, 95% CI = 1.61–12.10,
p = 0.004).
Since missing data were not equally distributed between the
hospital datasets, we cannot ignore that missing data are not
random. Since missing data at random assumption are not
testable, we used complete case analysis as a better approach
because multiple imputations could give rise to biased results.
Nevertheless, a sensitivity analysis in which missing outcomes
were imputed by multiple imputations was also carried out, and
this analysis showed similar results, which suggests a limited
effect of bias and strengthens the results obtained.
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